High Infiltration of CD203c+ Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer
Jing Li,Yuzhen Mo,Qingqing Wei,Jian Chen,Guozeng Xu
DOI: https://doi.org/10.2147/JIR.S400233
IF: 4.5
2023-02-22
Journal of Inflammation Research
Abstract:Jing Li, 1, &ast Yuzhen Mo, 2, &ast Qingqing Wei, 1 Jian Chen, 3 Guozeng Xu 1 1 Department of Oncology, Liuzhou People's Hospital of Guangxi Medical University, Liuzhou, Guangxi, People's Republic of China; 2 Department of Radiation Oncology, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China; 3 Department of Medical Oncology, Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guozeng Xu; Jian Chen, Email ; Background: Activated mast cells (AMCs) have been fully researched in inflammation and allergic reactions. However, the protumoral role of AMCs and their biomarker CD203c has not yet been investigated in colorectal cancer (CRC). Methods: We retrospectively collected 449 postoperative patients with stage II–III CRC at two different hospitals as the training (n=310) and validation (n=139) cohorts. These findings were further validated in the independent cohort (Integration of GSE39582 and GSE17536, n=489). The AMC density was assessed using CD203c staining or the CIBERSORT method. The main analysis was recurrence-free survival (RFS) and overall survival (OS). Results: As an independent factor, high AMC infiltration was associated with worse RFS/OS in the training (hazard ratio [HR]=3.437/3.014, all p < 0.001) and validation (HR=3.537/2.382, all p < 0.001) cohorts. We developed and validated an AMC-based nomogram for better stratification for postoperative recurrence in these two cohorts. The role of AMC density was further validated in the independent cohort. High AMC infiltration was associated with decreased RFS/OS after adjuvant chemotherapy (all p < 0.05). Approximately 74.2% of intramural CD203c + AMCs expressed a high level of PD-L1. Multiple immunosuppressive pathways were enriched in high AMC infiltration tumors, including upregulation of the TNF-α/NF-κB and angiogenesis pathways and downregulation of the IFN-γ and IFN-α responses. AMC infiltration was reversely associated with CD8 + T-cell infiltration (all p < 0.05). Conclusion: High AMC infiltration is associated with worse survival outcomes in stages II–III CRC. AMC density may serve as a potential biomarker for survival benefit in patients receiving adjuvant chemotherapy. This AMC-based nomogram could provide better recurrence stratification. Immunosuppression in tumors with high AMC infiltration might contribute to promoting tumor progression. Keywords: CD203c, colorectal cancer, activated mast cell, immunosuppression, prognostic benefit Mast cells have been fully researched in inflammation and allergic reactions. 1–3 Mast cells are an immune cellular subtype of the tumor microenvironment (TME). 4 However, the prognostic role of mast cells remains largely unknown in most tumors. Mast cells may generate many cytokines and play a crucial role in tumor progression. 4 Mast cells also interact with other immune cells to regulate tumor progression in the TME. 5,6 Accumulating evidence indicates that tryptase is expressed in almost all mast cells and thus labeled a pan-biomarker of mast cells. 7–11 However, there is no consistent opinion about the role of tryptase + mast cells in colorectal cancer (CRC). Several studies revealed that high infiltration of tryptase + mast cells was remarkably related to better treatment outcome, 7–10 whereas most studies supported that its high infiltration was markedly associated with worse prognosis. 11–18 This may attributed to a pan-biomarker of tryptase for mast cells, which could not effectively differentiate mast cells in different states. According to the activated state, mast cells are classified into two subtypes, including resting mast cells and activated mast cells (AMCs). As a surface biomarker of AMCs, CD203c is highly expressed in gynecologic cancer, renal cell cancer, and CRC. 19–21 However, no study has revealed the relationship between CD203c + AMCs and CRC prognosis. Therefore, we assessed the prognostic role of CD203c + AMCs in the training and validation cohorts. We developed and validated an AMC-based nomogram using CD203c staining in these two cohorts. The protumor role of AMC density was further validated in the combined microarray cohort by the CIBERSORT algorithm. We further performed gene set enrichment analysis (GSEA) to explore the crosstalk between AMCs and TME in a microarray dataset (GSE39582). We retrospectively collected 449 CRC patients at t -Abstract Truncated-
immunology